BCL-2 is dispensable for thrombopoiesis and platelet survival

MA Debrincat, I Pleines, M Lebois , RM Lane, ML Holmes, J Corbin, CJ Vandenberg, WS Alexander, AP Ng, A Strasser, P Bouillet, M Sola-Visner, BT Kile, EC Josefsson

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Navitoclax (ABT-263), an inhibitor of the pro-survival BCL-2 family proteins BCL-2, BCL-XL and BCL-W, has shown clinical efficacy in certain BCL-2-dependent haematological cancers, but causes dose-limiting thrombocytopaenia. The latter effect is caused by Navitoclax directly inducing the apoptotic death of platelets, which are dependent on BCL-XLfor survival. Recently, ABT-199, a selective BCL-2 antagonist, was developed. It has shown promising anti-leukaemia activity in patients whilst sparing platelets, suggesting that the megakaryocyte lineage does not require BCL-2. In order to elucidate the role of BCL-2 in megakaryocyte and platelet survival, we generated mice with a lineage-specific deletion of Bcl2, alone or in combination with loss of Mcl1 or Bclx. Platelet production and platelet survival were analysed. Additionally, we made use of BH3 mimetics that selectively inhibit BCL-2 or BCL-XL. We show that the deletion of BCL-2, on its own or in concert with MCL-1, does not affect platelet production or platelet lifespan. Thrombocytopaenia in Bclx-deficient mice was not affected by additional genetic loss or pharmacological inhibition of BCL-2. Thus, BCL-2 is dispensable for thrombopoiesis and platelet survival in mice.

Original languageEnglish
Article numbere1721
Number of pages8
JournalCell Death and Disease
Volume6
Issue number4
DOIs
Publication statusPublished - 16 Apr 2015
Externally publishedYes

Cite this

Debrincat, MA., Pleines, I., Lebois , M., Lane, RM., Holmes, ML., Corbin, J., ... Josefsson, EC. (2015). BCL-2 is dispensable for thrombopoiesis and platelet survival. Cell Death and Disease, 6(4), [e1721]. https://doi.org/10.1038/cddis.2015.97
Debrincat, MA ; Pleines, I ; Lebois , M ; Lane, RM ; Holmes, ML ; Corbin, J ; Vandenberg, CJ ; Alexander, WS ; Ng, AP ; Strasser, A ; Bouillet, P ; Sola-Visner, M ; Kile, BT ; Josefsson, EC. / BCL-2 is dispensable for thrombopoiesis and platelet survival. In: Cell Death and Disease. 2015 ; Vol. 6, No. 4.
@article{2cb5f0d2ff524610b822b2bd90ac8e3d,
title = "BCL-2 is dispensable for thrombopoiesis and platelet survival",
abstract = "Navitoclax (ABT-263), an inhibitor of the pro-survival BCL-2 family proteins BCL-2, BCL-XL and BCL-W, has shown clinical efficacy in certain BCL-2-dependent haematological cancers, but causes dose-limiting thrombocytopaenia. The latter effect is caused by Navitoclax directly inducing the apoptotic death of platelets, which are dependent on BCL-XLfor survival. Recently, ABT-199, a selective BCL-2 antagonist, was developed. It has shown promising anti-leukaemia activity in patients whilst sparing platelets, suggesting that the megakaryocyte lineage does not require BCL-2. In order to elucidate the role of BCL-2 in megakaryocyte and platelet survival, we generated mice with a lineage-specific deletion of Bcl2, alone or in combination with loss of Mcl1 or Bclx. Platelet production and platelet survival were analysed. Additionally, we made use of BH3 mimetics that selectively inhibit BCL-2 or BCL-XL. We show that the deletion of BCL-2, on its own or in concert with MCL-1, does not affect platelet production or platelet lifespan. Thrombocytopaenia in Bclx-deficient mice was not affected by additional genetic loss or pharmacological inhibition of BCL-2. Thus, BCL-2 is dispensable for thrombopoiesis and platelet survival in mice.",
author = "MA Debrincat and I Pleines and M Lebois and RM Lane and ML Holmes and J Corbin and CJ Vandenberg and WS Alexander and AP Ng and A Strasser and P Bouillet and M Sola-Visner and BT Kile and EC Josefsson",
year = "2015",
month = "4",
day = "16",
doi = "10.1038/cddis.2015.97",
language = "English",
volume = "6",
journal = "Cell Death and Disease",
issn = "2041-4889",
publisher = "Nature Publishing Group",
number = "4",

}

Debrincat, MA, Pleines, I, Lebois , M, Lane, RM, Holmes, ML, Corbin, J, Vandenberg, CJ, Alexander, WS, Ng, AP, Strasser, A, Bouillet, P, Sola-Visner, M, Kile, BT & Josefsson, EC 2015, 'BCL-2 is dispensable for thrombopoiesis and platelet survival' Cell Death and Disease, vol. 6, no. 4, e1721. https://doi.org/10.1038/cddis.2015.97

BCL-2 is dispensable for thrombopoiesis and platelet survival. / Debrincat, MA; Pleines, I; Lebois , M; Lane, RM; Holmes, ML; Corbin, J; Vandenberg, CJ; Alexander, WS; Ng, AP; Strasser, A; Bouillet, P; Sola-Visner, M; Kile, BT; Josefsson, EC.

In: Cell Death and Disease, Vol. 6, No. 4, e1721, 16.04.2015.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - BCL-2 is dispensable for thrombopoiesis and platelet survival

AU - Debrincat, MA

AU - Pleines, I

AU - Lebois , M

AU - Lane, RM

AU - Holmes, ML

AU - Corbin, J

AU - Vandenberg, CJ

AU - Alexander, WS

AU - Ng, AP

AU - Strasser, A

AU - Bouillet, P

AU - Sola-Visner, M

AU - Kile, BT

AU - Josefsson, EC

PY - 2015/4/16

Y1 - 2015/4/16

N2 - Navitoclax (ABT-263), an inhibitor of the pro-survival BCL-2 family proteins BCL-2, BCL-XL and BCL-W, has shown clinical efficacy in certain BCL-2-dependent haematological cancers, but causes dose-limiting thrombocytopaenia. The latter effect is caused by Navitoclax directly inducing the apoptotic death of platelets, which are dependent on BCL-XLfor survival. Recently, ABT-199, a selective BCL-2 antagonist, was developed. It has shown promising anti-leukaemia activity in patients whilst sparing platelets, suggesting that the megakaryocyte lineage does not require BCL-2. In order to elucidate the role of BCL-2 in megakaryocyte and platelet survival, we generated mice with a lineage-specific deletion of Bcl2, alone or in combination with loss of Mcl1 or Bclx. Platelet production and platelet survival were analysed. Additionally, we made use of BH3 mimetics that selectively inhibit BCL-2 or BCL-XL. We show that the deletion of BCL-2, on its own or in concert with MCL-1, does not affect platelet production or platelet lifespan. Thrombocytopaenia in Bclx-deficient mice was not affected by additional genetic loss or pharmacological inhibition of BCL-2. Thus, BCL-2 is dispensable for thrombopoiesis and platelet survival in mice.

AB - Navitoclax (ABT-263), an inhibitor of the pro-survival BCL-2 family proteins BCL-2, BCL-XL and BCL-W, has shown clinical efficacy in certain BCL-2-dependent haematological cancers, but causes dose-limiting thrombocytopaenia. The latter effect is caused by Navitoclax directly inducing the apoptotic death of platelets, which are dependent on BCL-XLfor survival. Recently, ABT-199, a selective BCL-2 antagonist, was developed. It has shown promising anti-leukaemia activity in patients whilst sparing platelets, suggesting that the megakaryocyte lineage does not require BCL-2. In order to elucidate the role of BCL-2 in megakaryocyte and platelet survival, we generated mice with a lineage-specific deletion of Bcl2, alone or in combination with loss of Mcl1 or Bclx. Platelet production and platelet survival were analysed. Additionally, we made use of BH3 mimetics that selectively inhibit BCL-2 or BCL-XL. We show that the deletion of BCL-2, on its own or in concert with MCL-1, does not affect platelet production or platelet lifespan. Thrombocytopaenia in Bclx-deficient mice was not affected by additional genetic loss or pharmacological inhibition of BCL-2. Thus, BCL-2 is dispensable for thrombopoiesis and platelet survival in mice.

UR - http://www.scopus.com/inward/record.url?scp=84989962172&partnerID=8YFLogxK

U2 - 10.1038/cddis.2015.97

DO - 10.1038/cddis.2015.97

M3 - Article

VL - 6

JO - Cell Death and Disease

JF - Cell Death and Disease

SN - 2041-4889

IS - 4

M1 - e1721

ER -

Debrincat MA, Pleines I, Lebois M, Lane RM, Holmes ML, Corbin J et al. BCL-2 is dispensable for thrombopoiesis and platelet survival. Cell Death and Disease. 2015 Apr 16;6(4). e1721. https://doi.org/10.1038/cddis.2015.97